AsianScientist (Sep. 26, 2013) – Amgen and ShanghaiTech University today announced a strategic partnership for the advancement of biopharmaceutical discovery and translational research in China.
This agreement includes plans for Amgen to open a China research and development (R&D) center at ShanghaiTech University, a research university jointly sponsored and organized by the Shanghai Municipal Government and the Chinese Academy of Sciences (CAS), with the former being responsible for its daily operation.
“Amgen and ShanghaiTech University share mutual goals of scientific excellence and rigor and will benefit from each other’s strength and expertise in advancing biopharmaceutical discovery in China,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.
“Expansion into China is a business priority for Amgen and opening this R&D center is another clear and important step forward in Amgen’s commitment to the China market.”
Under the terms of the MOU, Amgen will co-locate its China R&D center with ShanghaiTech University’s two life science institutes: the Shanghai Institute for Advanced Immunochemical Studies (SIAIS) and the iHuman Institute.
“We are pleased to be partnering with Amgen,” said Professor Mianheng Jiang, chairman of Executive Committee of ShanghaiTech University. “ShanghaiTech aims to build a research-oriented university that provides a dynamic approach to learning and ultimately solving problems facing society. This partnership is a commitment to develop more effective bio-medicine for the benefits of the patients in China and in the whole world.”
Amgen expects its China R&D center will be fully operational in 2014.
——
Source: Amgen.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
